Telix Pharmaceuticals Ltd (TLPPF) — 6-K Filings

6-K Filings (33)

• Telix Pharma Updates China Study, FDA Resubmissions — Dec 22, 2025 Risk: medium
  On December 22, 2025, Telix Pharmaceuticals Limited announced updates regarding its precision medicine portfolio. Key developments include the initiation of a P
• Telix Pharmaceuticals Files ProstACT Global Study Update — Dec 17, 2025 Risk: low
  On December 17, 2025, Telix Pharmaceuticals Limited announced the status of its ProstACT Global Study. The company filed this update as part of its Form 6-K wit
• 6-K Filing — Dec 8, 2025
• Telix Pharmaceuticals Upgrades FY25 Guidance on Strong Q3 — Oct 14, 2025 Risk: medium
  On October 14, 2025, Telix Pharmaceuticals Ltd announced strong third-quarter results, reporting US$206 million in revenue. The company also upgraded its fiscal
• Telix Pharmaceuticals' Goz نتix Gets CMS Pass-Through Status — Sep 23, 2025 Risk: low
  On September 23, 2025, Telix Pharmaceuticals Limited announced that the Centers for Medicare & Medicaid Services (CMS) has granted transitional pass-through sta
• Telix Pharmaceuticals and FDA Agree on Pixclara NDA Resubmission — Sep 9, 2025 Risk: medium
  On September 9, 2025, Telix Pharmaceuticals Limited announced an agreement with the FDA on a resubmission pathway for its Pixclara NDA. This development follows
• Telix Pharmaceuticals Files NDA for TLX250-CDx with FDA — Aug 28, 2025 Risk: medium
  On August 28, 2025, Telix Pharmaceuticals Limited announced a regulatory update regarding its TLX250-CDx product. The company has submitted a New Drug Applicati
• Telix Pharmaceuticals Ltd Files H1 2025 Results — Aug 21, 2025 Risk: low
  On August 21, 2025, Telix Pharmaceuticals Limited announced its H1 2025 results, including a presentation, Appendix 4D, and interim report. The company is a for
• Telix Pharmaceuticals Reports $240M Q2 Revenue, Up 63% YoY — Jul 22, 2025 Risk: low
  Telix Pharmaceuticals Limited announced on July 22, 2025, that its Q2 revenue reached US$240 million, marking a significant 63% year-over-year increase. This an
• Telix Pharmaceuticals' Gozellix Gets Permanent US Reimbursement Code — Jul 9, 2025 Risk: low
  On July 9, 2025, Telix Pharmaceuticals Limited announced that its product Gozellix received a permanent HCPCS code from the Centers for Medicare & Medicaid Serv
• Telix Pharmaceuticals Files Investor Day Presentation — Jun 11, 2025 Risk: low
  On June 11, 2025, Telix Pharmaceuticals Limited filed a Form 6-K with the SEC, attaching their "Telix Investor Day Presentation." This presentation, filed with
• Telix Pharmaceuticals Ltd Files AGM Results — May 21, 2025 Risk: low
  On May 21, 2025, Telix Pharmaceuticals Limited filed three announcements with the Australian Securities Exchange regarding its Annual General Meeting. These inc
• Telix Pharmaceuticals Provides Regulatory Update on TLX101-CDx — Apr 29, 2025 Risk: low
  On April 28, 2025, Telix Pharmaceuticals Limited announced a regulatory update regarding its TLX101-CDx product. The company filed an announcement with the Aust
• Telix Pharmaceuticals Reports $186M Q1 Revenue, Up 62% — Apr 22, 2025 Risk: low
  Telix Pharmaceuticals Ltd reported its first-quarter 2025 financial results on April 22, 2025, announcing a significant year-over-year revenue increase of 62% t
• Telix Pharmaceuticals TLX101 Shows Promising Glioma Efficacy — Apr 17, 2025 Risk: medium
  On April 16, 2025, Telix Pharmaceuticals Limited announced promising efficacy results for its TLX101 drug candidate in treating glioma. The announcement, filed
• Telix Pharmaceuticals Responds to US Government Actions — Apr 8, 2025 Risk: medium
  On April 7, 2025, Telix Pharmaceuticals Limited filed a Form 6-K with the SEC, attaching a press release titled "Telix Responds to Recent U.S. Government Action
• Telix Pharmaceuticals Appoints Anne Whitaker as Director — Apr 4, 2025 Risk: low
  On April 4, 2025, Telix Pharmaceuticals Limited announced the appointment of Anne Whitaker as a Non-Executive Director. This appointment was filed with the Aust
• FDA Approves Telix Pharmaceuticals' Prostate Cancer Agent — Mar 21, 2025 Risk: low
  On March 21, 2025, Telix Pharmaceuticals Limited announced that the U.S. Food and Drug Administration (FDA) has approved its new prostate cancer imaging agent,
• Telix Pharmaceuticals' Illuccix Approved in Brazil — Mar 18, 2025 Risk: low
  On March 18, 2025, Telix Pharmaceuticals Limited announced that its product, Illuccix, received approval in Brazil. This marks the first PSMA-PET approval in th
• Telix Pharmaceuticals Completes Theranostic Acquisition — Mar 12, 2025 Risk: low
  On March 12, 2025, Telix Pharmaceuticals Limited announced the completion of its acquisition of a FAP-targeting theranostic asset. The company filed this announ
• Telix CEO to Sell Shares — Feb 27, 2025 Risk: medium
  On February 26, 2025, Telix Pharmaceuticals Limited announced a pending sale of shares by its CEO. The specific details of the sale, including the number of sha
• FDA Grants Priority Review for Telix's Zircaix — Feb 26, 2025 Risk: medium
  On February 26, 2025, Telix Pharmaceuticals Limited announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (B
• Telix Pharmaceuticals Announces Board Renewal — Feb 25, 2025 Risk: low
  Telix Pharmaceuticals Limited announced on February 26, 2025, that it has made changes to its board of directors. This announcement was made via an Australian S
• Telix Pharmaceuticals Changes Reporting Currency to USD — Feb 24, 2025 Risk: low
  On February 25, 2025, Telix Pharmaceuticals Limited announced a change in its reporting currency from Australian Dollars (AUD) to United States Dollars (USD). T
• Telix Pharmaceuticals Files 2024 Annual Report & Results — Feb 21, 2025 Risk: low
  On February 20, 2025, Telix Pharmaceuticals Limited filed its Appendix 4E and 2024 Annual Report, along with its Appendix 4G and 2024 Corporate Governance State
• Telix Pharmaceuticals' Illuccix Approved in UK — Feb 13, 2025 Risk: low
  On February 13, 2025, Telix Pharmaceuticals Limited announced the approval of its product Illuccix in the United Kingdom. This marks a significant market expans
• Telix Pharmaceuticals Completes Tx Assets Acquisition — Jan 31, 2025 Risk: low
  On January 31, 2025, Telix Pharmaceuticals Limited announced the completion of its acquisition of Tx Assets and its Biologics Platform. This acquisition was fil
• Telix Pharmaceuticals Completes Acquisition of RLS (USA) Inc. — Jan 27, 2025 Risk: low
  On January 28, 2025, Telix Pharmaceuticals Limited announced the completion of its acquisition of RLS (USA) Inc. The company filed this announcement with the Au
• Telix Pharmaceuticals' Illucix® Gains European Approval — Jan 17, 2025 Risk: low
  On January 17, 2025, Telix Pharmaceuticals Limited announced that its product, Illucix®, has received European approval. This significant milestone allows for t
• Telix Pharmaceuticals to Acquire Next-Gen Therapeutics Platform — Jan 13, 2025 Risk: medium
  On January 13, 2025, Telix Pharmaceuticals Ltd announced its intention to acquire Next-Gen Therapeutics and Biologics Platform. This strategic move aims to enha
• Telix Pharmaceuticals Files BLA for Kidney Cancer Imaging Agent — Dec 30, 2024 Risk: medium
  On December 30, 2024, Telix Pharmaceuticals Limited announced it has filed a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA
• Telix Pharmaceuticals Adds FAP-Targeting Candidates to Pipeline — Nov 19, 2024 Risk: medium
  On November 19, 2024, Telix Pharmaceuticals Limited announced its intention to add two new Fibroblast Activation Protein (FAP)-targeting candidates to its thera
• Telix Pharmaceuticals ADSs Begin Trading on Nasdaq — Nov 14, 2024 Risk: medium
  Telix Pharmaceuticals Ltd announced on November 14, 2024, that its American Depositary Shares (ADSs) have commenced trading on the Nasdaq stock exchange. This m

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX